We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arm Holdings Plc ADS Each Representing 3 Ordinary Shares (MM) | NASDAQ:ARMH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 67.77 | 67.63 | 67.75 | 0 | 01:00:00 |
From May 2019 to May 2024
International stocks trading in New York were mixed Monday, with the Bank of New York index of American depositary receipts rising 0.14% to 154.19. The European index decreased 0.04% to 154.55, the Asian index improved 0.75% to 145.83, the Latin American index fell 0.21% to 279.93 and the emerging markets index increased 0.31% to 280.52. Among the companies with shares that actively traded was Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV).
Teva unveiled an organizational revamp that includes slashing the size of its executive committee and appointing a global quality-control chief. The Israel-based drug maker plans to combine its generic operations into a global generic medicines unit that will be led by Sigurdur Olafsson, who has been named president and chief executive of the business effective July 1. Mr. Olafsson's experience includes serving as president of Actavis PLC. Teva shares rose 2.9% to $51.95.
ARM Holdings PLC (ARMH, ARM.LN), whose chip designs are found in more than 90% of mobile phones, is gearing up to develop chips for wearable devices, which are expected to be a high-growth market in coming years. U.K.-based ARM said Monday it is building a design center in Taiwan, the company's fourth world-wide, to develop chips for accessories like watches and glasses and for electronic devices that connect with one another and with the Internet. Shares fell 0.3% to $46.08.
A combination of two experimental AstraZeneca PLC (AZN, AZN.LN) drugs, olaparib and cediranib, held ovarian cancer at bay for 17.7 months in a clinical trial, compared with nine months in patients who received olaparib alone. Results of the study, conducted by the National Cancer Institute, were presented over the weekend at the American Society of Clinical Oncology meeting. AstraZeneca, which has been developing each drug individually, says it supports National Cancer Institute's plan to further test the combination in additional trials. AstraZeneca shares rose 1.6% to $73.37.
Australian mining giant BHP Billiton (BHP, BHP.AU) says that it is living proof that big companies aren't doomed to fail in shale. BHP says it faced a steep learning curve when it bought shale producer Petrohawk in 2011 for $12 billion. "The first year was tough. I mean, our costs were high," said Rod Skaufel, BHP's shale president. But a more nimble strategy and scientific approach has helped the company slash costs by 25% in some areas, he says. BHP Billiton shares rose 0.4% to $68.16.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Arm Holdings Plc ADS Each Representing 3 Ordinary Shares (MM) Chart |
1 Month Arm Holdings Plc ADS Each Representing 3 Ordinary Shares (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions